Rexroth Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Profit Growth -1.30%
- Ebitda
- Net Worth -1.93%
- Total Assets -0.06%
About Rexroth Pharmaceutical
Rexroth Pharmaceutical Limited (RPL) is a Public Limited Indian Non-Government Company incorporated in India on 15 May 2013 and has a history of 11 years and eight months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjaykumar Trivedi, Ketankumar Trivedi, and Sanjaykumar Shah serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232GJ2013PLC075081
-
Company No.
075081
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
15 May 2013
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Rexroth Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaykumar Trivedi
|
Director | 15-May-2013 | Current |
|
Ketankumar Trivedi
|
Director | 15-May-2013 | Current |
|
Sanjaykumar Shah
|
Director | 15-May-2013 | Current |
Financial Performance of Rexroth Pharmaceutical.
Rexroth Pharmaceutical Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 1.3% decrease in profit. The company's net worth dipped by a decrease of 1.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rexroth Pharmaceutical?
In 2016, Rexroth Pharmaceutical had a promoter holding of 99.20% and a public holding of 0.80%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Seva Healthcare Private LimitedSanjaykumar Trivedi and Ketankumar Trivedi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rexroth Pharmaceutical?
Unlock and access historical data on people associated with Rexroth Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rexroth Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rexroth Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.